FDA Drug Recalls

Recalls / Class III

Class IIID-1034-2018

Product

Levofloxacin Injection in 5% Dextrose, 250 mg (5 mg/mL), 250 mg in 50 mL 5% Dextrose, 50 mL Single Use Container bag, Rx only, Manufactured for: Claris Lifesciences Inc., North Brunswick, NJ 08902; By: Claris Injectables Ltd., Gujarat, India, NDC 36000-046-24.

Brand name
Levofloxacin
Generic name
Levofloxacin
Active ingredient
Levofloxacin
Route
Intravenous
NDCs
36000-045, 36000-046, 36000-047, 36000-048
FDA application
ANDA091436
Affected lot / code info
Lot #: A061178, A061183, A061236, Exp 09/18; A0A0937, Exp 08/19; A0A1044, A0A1048, Exp 10/19

Why it was recalled

Superpotent Drug: High out of specification results for levofloxacin resulting in increased concentration of solution.

Recalling firm

Firm
Baxter Healthcare Corporation
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
1 Baxter Pkwy, N/A, Deerfield, Illinois 60015-4625

Distribution

Quantity
191,256 bags
Distribution pattern
Nationwide USA and Puerto Rico

Timeline

Recall initiated
2018-08-01
FDA classified
2018-08-03
Posted by FDA
2018-08-15
Terminated
2020-07-16
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-1034-2018. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class III recall: Levofloxacin · FDA Drug Recalls